Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

 Breaking News
  • No posts were found

Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

December 05
20:36 2023
Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Osteoarthritis Pipeline Report

  • DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
  • The leading companies working in the Osteoarthritis Market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Promising Osteoarthritis Pipeline Therapies in the various stages of development include Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.
  • October 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Fasinumab. The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
  • October 2023: Biosplice Therapeutics Inc. announced a study of Phase 3 clinical trials for Lorecivivint. This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.

 

Request a sample and discover the recent advances in Osteoarthritis Treatment Drugs @ Osteoarthritis Pipeline Report

 

In the Osteoarthritis pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, Osteoarthritis clinical trials, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected.

 

Find out more about Osteoarthritis Therapeutics Assessment @ Osteoarthritis Preclinical and Discovery Stage Products

 

Osteoarthritis Emerging Drugs Profile

  • Lorecivivint: Biosplice Therapeutics
  • CYP 004: Cynata Therapeutics
  • JTA-004: Bone Therapeutics
  • SMUP-IA-01: Medipost
  • TTAX03: Tissue Tech

 

Osteoarthritis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

 

DelveInsight’s Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

 

Osteoarthritis Pipeline Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Osteoarthritis Pipeline Therapies @ Osteoarthritis Clinical Trials Assessment

 

Scope of the Osteoarthritis Pipeline Report

  • Coverage- Global
  • Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Osteoarthritis Pipeline Therapies- Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.

 

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, Visit @ Osteoarthritis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Osteoarthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Osteoarthritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lorecivivint: Biosplice Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TTAX03: Tissue Tech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GLPG-0555: Gilead Sciences
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Protego-PD: Plakous Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Osteoarthritis Key Companies
  21. Osteoarthritis Key Products
  22. Osteoarthritis- Unmet Needs
  23. Osteoarthritis- Market Drivers and Barriers
  24. Osteoarthritis- Future Perspectives and Conclusion
  25. Osteoarthritis Analyst Views
  26. Osteoarthritis Key Companies
  27. Appendix

 

For further information on the Osteoarthritis Pipeline therapeutics, reach out to Osteoarthritis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Related Articles

Categories